Adult Neurodevelopmental Services. ADHD Shared Protocol
|
|
- Julius Ramsey
- 6 years ago
- Views:
Transcription
1 Adult Neurodevelopmental Services ADHD Shared Protocol Issue 1: April
2 2 Adult Neurodevelopmental Service Shared Care Protocol for Adult Attention Deficit Hyperactivity Disorder (ADHD) 1. BACKGROUND 1.1 ADHD is a neuro-developmental condition which manifests as cognitive and behavioural deficits. It is characterised by the core symptoms of hyperactivity, impulsivity and inattention. ADHD is thought to be a persistent condition and a diagnosis of adult ADHD should only be made by a specialist psychiatrist or appropriately qualified healthcare professional with training and expertise in the diagnosis of ADHD. 1.2 It is now widely recognised that in up to 78% (Faraone et al 2010) of ADHD patients the condition continues into adulthood and continues to cause impairment of functioning in a large proportion of these patients. Hence these patients need continuation of their treatment. 1.3 NICE clinical guidelines on the treatment of ADHD (2008) recognises drug treatment of ADHD as part of a comprehensive treatment programme addressing psychological, behavioural and educational or occupational needs. However, it considers drug treatment as the first line treatment unless the person prefers psychological treatment. 1.4 However a comprehensive treatment programme can only be provided by a multi-disciplinary service fully funded for this purpose. The newly developed DWMH Adult Neurodevelopmental Service has not been fully funded by the commissioners and will be provided on a spot purchase basis, therefore at this early stage the Trust will be providing only a limited service to individual named patients for whom this service has been requested and funded by commissioners. 1.5 This service will not be able to address psychological, behavioural and educational or occupational needs of these patients at this stage but initial assessment will identify those needs and Primary Care Physicians will be expected to access the required services through local authorities, IAPT or voluntary organisations. 1.6 The limited service that the Trust we currently provides includes assessment, diagnosis, recommending drug treatment, reviews for optimising the medication and annual reviews thereafter.
3 2 DRUG TREATMENT OF ADHD IN ADULTS 2.1 NICE; Full guideline Draft (2008) recognised that the treatment strategies for ADHD in adults was essentially similar to those used in childhood. It also very importantly stated that it remains an anomaly that many drugs that are considered to be safe and effective in children and adolescents are not licensed for use in adults. 2.2 The British Association for Psychopharmacology (BAP) 2006; Evidencebased Guidelines for Management of ADHD, addressed the issue of off-license prescribing. It observed that the BNF (Joint Formulary Committee 2005) stated; unlicensed use of medicines becomes necessary if the clinical need cannot be met by licensed medicines; such use should be supported by appropriate evidence and experience. 2.3 BAP Guidelines further state: Although controlled evidence for prescribing in adults is not extensive, this consensus statement can be considered to meet the criteria for adequate evidence and experience when prescribing standard medications to adults with ADHD, when done in the context or with support of specialist psychiatric services. 2.4 Concerta XL, Medikinet XL and lisdexamfetamine are licensed for use in adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment. Atomoxetine is licensed for initiation in adulthood. Elvanse Adult (lisdexamfetamine) has recently been given licence for treatment initiation in adults. 2.5 Prescribers should always consider any risk/potential of addiction, misuse or diversion as part of their initial assessment. 3. PATHWAYS OF RFERRAL TO ADULT NEURODEVELOPMENTAL SERVICE 3.1 All referrals should initially be sent to: 3
4 Dr. S H Jawed Consultant Psychiatrist, Adult Neurodevelopmental Service Dorothy Pattison Hospital Alumwell Close Walsall West Midlands WS2 9XH Dr. R Joseph Consultant Psychiatrist, Adult Neurodevelopmental Service Bushey Fields Hospital Bushey Fields Road Dudley West Midlands DY1 2LZ 3.2 Referrals will then be screened by Dr. Jawed and Dr. Joseph. 3.3 Once accepted, referral will be passed on to Commissioning Department to secure the funding approval from relevant CCGs If the referral is considered to be appropriate for the service but funding has not been agreed with the CCG, the Adult neurodevelopmental Service s admin staff will seek funding approval from the relevant CCG. 3.4 On funding approval, appointment letters will be sent out by the Adult Neurodevelopmental Service s admin staff. Letters will also be sent out to PCPs informing them of the appointments and requesting addition information (if required) and baseline physical examination and investigations that PCP should carry out prior to initiation of treatment. 3.5 The funding may be requested for one or more of these assessment pathways, as advised by Dr. Jawed/Dr. Joseph Patients never formally diagnosed Patients previously diagnosed requesting treatment Patient already on treatment, needing review Annual Reviews for patients To be completed yearly Full New patient Assessment for Diagnosis & Treatment New Patient Baseline Assessment New Patient Baseline Assessment Annual Review 4
5 4. RESPONSIBILITIES 4.1 Responsibilities of Adult Neurodevelopmental Service Diagnosis of ADHD based on comprehensive assessment Recording pre-treatment measurement of weight, pulse rate and blood pressure. A full history and physical examination including: o Assessment of history of exercise syncope, undue breathlessness and other cardiovascular symptoms. o Family history of cardiac disease and examination of the cardiovascular system. To advise primary care physicians (PCP) on social, psychological and behavioural interventions that may be required. Adult Neurodevelopmental Service would not be providing these interventions. To identify co-morbid mental health conditions and advise the PCP to refer the patient to the Adult Mental Health Services if required. To advise on initiating and stabilising treatment with Methylphenidate, Dexamfetamine, Lisdexamphetamine and Atomoxetine. Communicate to PCP which brand of methylphenidate long acting is prescribed, as different brands are not interchangeable. Discuss the benefits and side effects of treatment with patient (including MHRA advice for Atomoxetine in relation to hepatic disorders and suicidal ideation/ self-harming behaviour) Explain the licensing of medicines and when medicines are used off label to the service user and carer and secure their written agreement (if applicable). Also discuss misuse and diversion issues. Send a letter to the PCP requesting shared care stating the patient s diagnosis. Carry out drug optimising and annual reviews as per funding agreement and communicate promptly with the PCP when treatment is changed. Advise the PCP on when to adjust the dose, discontinue treatment, or consult with the Adult Neurodevelopmental Service Ensure that clear backup arrangements exist for PCP to obtain advice and support. 4.2 Responsibilities of Primary Care Physicians To carry out baseline physical investigations as requested by the Adult Neurodevelopmental Service and communicate back the results to them Prescribe Methylphenidate, Dexamfetamine and Atomoxetine at the dose recommended by the Adult Neurodevelopmental service 5
6 Adjust the dose when advised by the Adult Neurodevelopmental service Report to and seek advice from the Adult Neurodevelopmental service on any aspect of patient care that is of concern and may affect treatment. Carry out regular physical checks and investigations as recommended by the license of each medication and communicate results back to Adult Neurodevelopmental Service. Carry out regular Clinical Monitoring as recommended by the NICE Guidelines and communicate any abnormal results back to Adult Neurodevelopmental Service. Current monitoring requirements which are subject to change include the following: o Weight: Weight to be measured 3rd and 6th month after initiation and six monthly thereafter. If evidence of weight loss monitor BMI, if weight loss persists refer back to prescribing professional. o Heart rate and Blood pressure: Chart before and after each dose change and routinely every three months. Sustained resting tachycardia, arrhythmia or clinically significant high systolic blood pressure after two measurements, consider dose after two measurements consider dose reduction and refer to physician. o Sexual dysfunction: Erectile and ejaculatory dysfunction also dysmenorrhoea should be monitored as potential side effects of Atomoxetine. Refer back to the Adult Neurodevelopmental Service, if the patient s condition deteriorates for a review. Specific triggers for referral back may include: Sustained resting tachycardia, arrhythmia or a clinically significant increase in systolic blood pressure measured on two occasions (reduce dose and refer) Anxiety symptoms, including panic Stop treatment on the advice of Adult Neurodevelopmental Service or immediately if an urgent need to stop treatment arises. Report adverse events to the prescribing professional and the MHRA/ CSM via Yellow card located in BNF or online Responsibilities of the Patients Report to the prescribing GP if he or she does not have a clear understanding of the treatment. Share any concerns in relation to treatment with methylphenidate, Dexamfetamine, Lisdexamhetamine and Atomoxetine. Inform prescribing GP of any other medication being taken, including overthe-counter products. 6
7 Report any adverse effects or warning symptoms to the prescribing GP whilst taking Methylphenidate, Dexamfetamine, Lisdexamhetamine and Atomoxetine. 4.4 Contact for support and advice Dr. S H Jawed Consultant Psychiatrist, Adult Neurodevelopmental Service Dorothy Pattison Hospital Alumwell Close Walsall West Midlands WS2 9XH Dr. R Joseph Consultant Psychiatrist, Adult Neurodevelopmental Service Bushey Fields Hospital Bushey Fields Road Dudley West Midlands DY1 2LZ References 1. DSM IV (Diagnostic and Statistical Manual American Psychiatric Association 2000) 2. Faraone SV, Spencer T, Aleardi M et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24: NICE Guideline Quick reference guide; 4. British Association for Psychopharmacology 2006; Evidence based guidelines for management of Attention-Deficit/hyperactivity Disorder in Adolescents in transition to Adult Services and in Adults 5. Ritalin, Concerta XL, EquasymXL, Medikinet XL,Elvanse Adult and 7
8 Atomoxetine Summary of Product Characteristics (accessed via 6. Essential Shared Care Agreement (South Staffordshire): Methylphenidate (immediate release and long acting), Dexamfetamine, and Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adults (E032 ADHD in Adults ESCA) 7. Full Shared Care Agreement for Methylphenidate, Dexamfetamine, Atomoxetine and Lisdexamfetamine for use in Attention Deficit Hyperactivity Disorder In Adults. On behalf of East Leicestershire and Rutland Clinical Commissioning Group, Leicester City Clinical Commissioning Group, West Leicestershire Clinical Commissioning Group, Leicestershire Partnership NHS Trust and University Hospitals of Leicester NHS Trust. Reviewed in February
9 9
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationIf a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable.
Shared Care Protocol for the Methylphenidate and the Management of Attention Deficit Hyperactivity Disorder (ADHD) for children from 4 years up to 17 years and 364 days 1.0 INTRODUCTION The medical assessment
More informationDr S H Jawed Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for
Dr S H Jawed Syed.Jawed@dwmh.nhs.uk 01922607039 Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for Adult Neurodevelopmental Service, DWMHP NHS Trust Regional
More informationMETHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a
More informationSHARED CARE PRESCRIBING GUIDELINE
Approval date: September 2018. Document review date: September 2021 or sooner if evidence/practice changes g SHARED CARE PRESCRIBING GUIDELINE Methylphenidate, atomoxetine, lisdexamfetamine, dexamfetamine
More informationKiran Hewitt Katie Sims. Dr Alex Day. Reviewed By Ozma Tahir Lead Medicines Information and Clinical Economy Pharmacist, BHFT
Prescribing Arrangements for the use of methylphenidate, atomoxetine, lisdexamfetamine and amfetamine in adult ADHD (attention deficit hyperactivity disorder) in Berkshire For all referrals of adults with
More informationIssue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist
Title Document Type Issue no Shared care guidelines in the Treatment of Attention Deficit/ Hyperactivity Disorders Shared Care Guidelines and Information for GPs Clinical Governance Support Team Use Issue
More informationAdult ADHD: How Big is the Problem? Delivering Effective Services for Adults with ADHD
Adult ADHD: How Big is the Problem? Delivering Effective Services for Adults with ADHD North West Mental Health Commissioning Network 1 st March 2016 Dr Prathiba Chitsabesan Consultant Child and Adolescent
More informationAttention deficit hyperactivity disorder
Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults Issued: September 2008 last modified: March 2013 NICE clinical guideline 72 guidance.nice.org.uk/cg72
More informationSHARED PRESCRIBING GUIDELINE
working in partnership with Kingston Richmond Wandsworth SHARED PRESCRIBING GUIDELINE Sutton & Merton Methylphenidate, Dexamfetamine and Atomoxetine for Attention Deficit Hyperactivity Disorder in patients
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationClinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72
Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2018. All rights reserved. Subject to Notice of rights
More informationChild and Adolescent Mental Health Services (CAMHS)
Child and Adolescent Mental Health Services (CAMHS) Effective shared care agreement (ESCA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with METHYLPHENIDATE This form must be completed
More informationE096. Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability
E096 Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability Please complete the following details: Patient s name, address, date of birth,
More informationDisclosures. Speakers and Consultancy fees from. Lundbeck Janssen Eli Lilly
Dr S H Jawed Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for Adult Neurodevelopmental Service, DWMHP NHS Trust Regional Lead, UK Adult ADHD Network (UKAAN)
More informationDiagnosis and management of ADHD in children, young people and adults
Issue date: September 2008 Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults NICE clinical guideline 72 Developed by the National Collaborating
More informationProtocol 02, v1.0, HMMC October of 22
Protocol 02: Methylphenidate, atomoxetine, dexamfetamine and lisdexamfetamine prescribing and monitoring guidance for treatment of Attention Deficit Hyperactivity Disorder in children, young people and
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More informationEssential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin)
Ref No: E056 Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Please complete the following details: Patient s name, address, date of birth, and either complete when the consultant
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: METHYLPHENIDATE Protocol number: CV 42
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: METHYLPHENIDATE Protocol number: CV 42 Indication: ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), HYPERKINETIC
More informationAttention Deficit Hyperactivity Disorder (ADHD) in adults Patient information leaflet
Attention Deficit Hyperactivity Disorder (ADHD) in adults Patient information leaflet Introduction This leaflet provides information about the condition Attention Deficit Hyperactivity Disorder (ADHD),
More informationADHD/Hyperkinetic Disorder for Children & Young People (6-17 years) - Methylphenidate, Atomoxetine, Dexamfetamine and Lisdexamfetamine
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name: Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Attention Deficit Hyperactivity Disorder
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationNikki Mallinder on behalf of Linda Honey. Karen Thorburn Date: 04/10/18
Agenda item: 7 ii Paper no: PCCC ic 20-18 Title of Report: Status: Committee: Venue: Update to the Attention Deficit Hyperactivity Disorder (ADHD) in Childhood) 12 monthly physical medication monitoring
More informationADHD. Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD)
ADHD Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD) This guide can help you to make a more informed choice about which medication may be best for you if you have been
More informationPrescribing framework for Dexamfetamine for Attention Deficit Hyperactive Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationAdult ADHD Service Development. Dr Joe Johnson Consultant Psychiatrist Five Boroughs Partnership NHS Trust
Adult ADHD Service Development Dr Joe Johnson Consultant Psychiatrist Five Boroughs Partnership NHS Trust Consultant Psychiatrist in 5BP since 2005 My Background Working both in Community and Prison MH
More informationDocument Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers
Document Details Title Shared Care Agreement Lisdexamfetamine Trust Ref No 1989-33708 Local Ref (optional) Main points the document covers The responsibilities of each partner entering into the shared
More informationA guide to Getting an ADHD Assessment as an adult in Scotland
A guide to Getting an ADHD Assessment as an adult in Scotland This is a guide for adults living in Scotland who think they may have ADHD and have not been diagnosed before. It explains: Things you may
More informationShared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved by Joint Medicines Operational Group 1/12/17
This policy statement is approved by Southport and Formby, and South Sefton CCGs Southport and Formby South Sefton Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved
More informationNorth Central London Joint Formulary Committee
North Central London Joint Formulary Committee Shared Care Guideline Methylphenidate (immediate release and long acting), Atomoxetine, Dexamfetamine and Lisdexamfetamine for treatment of Adult Attention
More informationPrescribing Framework for Lisdexamfetamine for Attention Deficit Hyperactivity Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Lisdexamfetamine for Attention Deficit Hyperactivity Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Personality disorder: the management and prevention of antisocial (dissocial) personality disorder 1.1 Short title Antisocial
More informationEffective Shared Care Agreement (ESCA) Methylphenidate (from age 6 years) Approved for Solihull locality only.
Effective Shared Care Agreement (ESCA) Methylphenidate (from age 6 years) Approved for Solihull locality only. ESCA: For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as part of a comprehensive
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationTo approve Primary Care Commissioning Committees in Common Date: 9/11/18. NWS CCG 58 Church St, Weybridge, Surrey, KT13 8DP
Agenda item: 9 Paper no: PCCC ic 31-18 Title of Report: Status: Committee: Attention Deficit Hyperactivity Disorder (ADHD) in children 6-17 years old - 12 monthly review monitoring for CNS stimulants,
More informationWorcestershire Area Prescribing Committee Guideline
Worcestershire Area Prescribing Committee Guideline Attention Deficit Hyperactivity Disorder (ADHD) in Adults, Adolescents and Children Prescribing Guidelines and Shared Care for GPs, locum doctors and
More informationQ. As noted in the NICE Quality Standard for ADHD ( can you please provide information on:
Q. As noted in the NICE Quality Standard for ADHD (https://www.nice.org.uk/guidance/qs39), can you please provide information on: 1. What proportion of children and young people with symptoms of ADHD have
More informationAdult ADHD for GPs. Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD
Adult ADHD for GPs Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD I m a Believer.. Are You? What is ADHD? ADHD is a valid clinical condition defined
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Personality Disorder: the clinical management of borderline personality disorder
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Personality Disorder: the clinical management of borderline personality disorder 1.1 Short title Borderline personality disorder
More informationMEDICINES MANAGEMENT FOR ADULT ADHD GLOUCESTERSHIRE PATHWAY. Before commencing treatment measure weight, blood pressure and heart rate.
MEDICINES MANAGEMENT FOR ADULT ADHD GLOUCESTERSHIRE PATHWAY ADULT ADHD MEDICATION TITRATION SCHEDULE Before commencing treatment measure weight, blood pressure and heart rate. CONCERTA XL Check heart rate/
More informationE100. Patient s name: Patient s address: Patient s Date of Birth:
E100 Essential Shared Care Agreement: Methylphenidate (immediate release and long acting), Dexamfetamine, Lisdexamfetamine and Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
More informationNICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng87
Attention deficit hyperactivity disorder: diagnosis and management NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng87 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationDrug and Alcohol Misuse Policy
Drug and Alcohol Misuse Policy MOHFC 22 Introduction 1. MOHFC recognises that alcohol and drug misuse related problems are an area of health and social concern. It also recognises that a member of staff
More informationPrescribing Framework for Guanfacine Hydrochloride (Intuniv) for Attention Deficit Hyperactivity Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Guanfacine Hydrochloride (Intuniv) for Attention Deficit Hyperactivity Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST SHARED CARE GUIDELINE: Methylphenidate, atomoxetine, dexamfetamine and lisdexamfetamine
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationProject Initiation Document:
Project Initiation Document: Lancashire Support Services for Children, Young People, Families and Carers Affected by Autistic Spectrum Disorder (ASD) and Diagnosis 1. Background The Children and Young
More informationPrescribing Framework for Methylphenidate for Attention Deficit Hyperactive Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Methylphenidate for Attention Deficit Hyperactive Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationPortsmouth and South East Hampshire Area Prescribing Committee. Shared Care Agreement. Licensed ADHD Medications for the Treatment of Childhood ADHD
Portsmouth and South East Hampshire Area Prescribing Committee Shared Care Agreement Licensed ADHD Medications for the Treatment of Childhood ADHD Produced by: Graham Brown, Children s and Younger Peoples
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP. Replaces: No previous version available. Management Committee 11 th March 2014
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP Methylphenidate and Dexamfetamine in children and adolescents: SHARED CARE GUIDELINE Scope:
More informationDrug, Alcohol & Substance Misuse September 2017
Drug, Alcohol & Substance Misuse September 2017 Office use Published: September 2016 Reviewed: September 2017 Next review: September 2018 Statutory/non: Non statutory Lead: Gary Corban Chief Operating
More informationTopic proposal. 1. What is the problem/need for a guideline/clinical scenario?
Topic proposal I understand that this proposal will be retained by the Programme Lead and be made available on the website for time period that the proposal is being considered. Only proposals with a completed
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationMental Health Strategy. Easy Read
Mental Health Strategy Easy Read Mental Health Strategy Easy Read The Scottish Government, Edinburgh 2012 Crown copyright 2012 You may re-use this information (excluding logos and images) free of charge
More informationAdult ADHD - New Models of Care
Adult ADHD - New Models of Care Mark Pitts Senior Clinical Nurse Specialist Adult ADHD Service, Maudsley Hospital & Lambeth Adult ADHD & Autism Service What is needed? NICE (2008) guidance postulates 1)
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationPatient Details: Section B: To be completed by the GP and returned to the Specialist Clinician detailed above
Shared Care Guideline Prescribing Agreement for single agent Attention Deficit Hyperactivity Disorder (ADHD) medication ATOMOXETINE in ADULT patients (over 18 years) Section A To be completed by the Specialist
More informationSHARED CARE AGREEMENT
SHARED CARE AGREEMENT CNS Stimulants and other drugs for Attention Deficit Hyperactivity Disorder (ADHD) in Children (,, hydrochloride) Version: Date: Author: Status: Comment: 6 31.01.2014 Dr Peter Coleman
More informationTHE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES
THIS GUIDELINE DESCRIBES THE PHARMACOLOGICAL MANAGEMENT OF Attention Deficit Hyperactivity Disorder IN THE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES
More informationAttention Deficit Hyperactivity Disorder
Page 1 of 5 Attention Deficit Hyperactivity Disorder ADHD is a common condition that mainly affects behaviour. Children with this condition show persistent restlessness, impulsiveness and/or inattention.
More informationADHD Guidance September 2013
ADHD Guidance September 2013 This guidance has been developed from the SASC convened ADHD Consensus Meeting chaired by Prof Philip Asherson held at Oxford University in May 2013 and subsequent consultations
More informationOutline & Objectives
21/11/2017 ADHD Assessment and brief Intervention service: a multi-disciplinary perspective Kapil Sayal Outline & Objectives To be aware of the service context and development To understand these aspects
More informationShared Care Guidelines. Shared Care Guidelines for Attention Deficit Hyperactivity Disorder in children:
Shared Care Guidelines Shared Care Guidelines for Attention Deficit Hyperactivity Disorder in children: BACKGROUND Attention Deficit Hyperactivity Disorder (ADHD) is a neuro-developmental condition affecting
More informationSubstance misuse: dual diagnosis, taking steps to improve care
Substance misuse: dual diagnosis, taking steps to improve care Presented by: Kerry Trinder, Head of Services for the Black Country Marcin Parakoyi MRCPsych, Consultant Psychiatrist Date: 20 th September
More informationFor children and adolescents and continued prescribing in patients transferred to adult services. For newly diagnosed adults
SHARED CARE PROTOCOL FOR: METHYLPHENIDATE, ATOMOXETINE, LISDEXAMFETAMINE and DEXAMFETAMINE FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) For children and adolescents and continued
More informationEssential Shared Care Agreement Naltrexone
In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy
More informationPrescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder and Narcolepsy
Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder and Narcolepsy Patient s Name: NHS Number: Patient s Address: (Use addressograph sticker) GP s Name:... Communication
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)
E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and
More informationNICE quality standard for attention deficit hyperactivity disorder (QS39)
QS 39 NICE quality standard for attention deficit hyperactivity disorder (QS39) NICE provided the content for this booklet which is independent of any company or product advertised 2 THE COMMISSIONING
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationDRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.
`Shared Care Guidelines DRUG: Introduction Inhaled antibiotics (Adults and Paediatrics) in Cystic Fibrosis. EXISTING ESTABLISHED PATIENTS ONLY Colistimethate (Colomycin, Promixin ) Tobramycin (Tobi Bramitob
More informationADHD. Treatment of ADHD
Shared care guideline for the use of Methylphenidate, Dexamfetamine, Lisdexamfetamine dimesylate & Atomoxetine for the management of Attention Deficit Hyperactivity Disorder (ADHD) in Adults (18-64years)
More informationDiagnosis and management of ADHD in children and adults
NEW FROM NICE Diagnosis and management of ADHD in children and adults STEVE CHAPLIN In March, NICE updated its guidance on the diagnosis and management of attention deficit hyperactivity disorder (ADHD)
More informationCAMHS - Childrens Scrutiny Panel Rutland Adam McKeown Head of FYPC Group 1 & Adult LD.
CAMHS - Childrens Scrutiny Panel Rutland Adam McKeown Head of FYPC Group 1 & Adult LD www.leicspart.nhs.uk Contents Overview of CAMHS Services provided by LPT Current overall CAMHS performance context
More informationAppendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children
Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationAutism Spectrum Conditions
Autism Spectrum Conditions June 2017 Produced by Abraham George: Public Health Consultant (abraham.george@kent.gov.uk) Gerrard Abi-Aad: Head of Health Intelligence (gerrard.abi-aad@kent.gov.uk) Correspondence
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationLondon Medicines Information Service
London Medicines Information Service Extended-release methylphenidate a review of the pharmacokinetic profiles available March 2018 First authored by Martin Bradley (martin.bradley@gstt.nhs.uk) May 2016
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationNICE guidance for ADHD: A guide for patients
NICE guidance for ADHD: A guide for patients NICE guideline: Attention deficit hyperactivity disorder: diagnosis and management. NG87. March 2018. Report was developed following a workshop and subsequent
More informationPrescribing classification: Amber with shared care. NOTES to the GP
SHARED CARE PRESCRIBING GUIDELINE LICENSED MEDICATIONS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDHOOD NOTE: to be used by practices participating in the locally commissioned
More informationAUTISM STRATEGY FOR ADULTS IN BIRMINGHAM
CONSULTATION DOCUMENT AUTISM STRATEGY FOR ADULTS IN BIRMINGHAM 2013 2016 HELPING ADULTS WITH AUTISM TO ACHIEVE FULFILLING AND REWARDING LIVES RAISING AWARENESS TO INFORM, IMPLEMENT AND IMPROVE Strategy
More informationAdult ADHD How Big is the Problem? National Perspective
Adult ADHD How Big is the Problem? National Perspective East Midlands Mental Health Commissioning Network Conference March 23rd 2016 Professor Chris Hollis Adult ADHD: National Perspective Adult ADHD:
More information02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST
Service Specification No. Service Commissioner Leads 02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical Provider Lead POOLE HOSPITAL NHS FOUNDATION TRUST Period 1 April 2013 to 31
More informationNew Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services
New Jersey Department of Children and Families Policy Manual Manual: CP&P Child Protection and Permanency Effective Volume: V Health Date: Chapter: A Health Services 1-11-2017 Subchapter: 1 Health Services
More information